Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
Public ClinicalTrials.gov record NCT03704714. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With R-CHOP in a Cohort of Patients With DLBCL/tFL/ High Grade B-NHL
Study identification
- NCT ID
- NCT03704714
- Recruitment status
- Suspended
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Northwestern University
- Other
- Enrollment
- 30 participants
Conditions and interventions
Conditions
- Aggressive Non-Hodgkin Lymphoma
- B-Cell Non-Hodgkin Lymphoma
- CD20 Positive
- Diffuse Large B-Cell Lymphoma Unclassifiable
- Intravascular Large B-Cell Lymphoma
- Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
- Cyclophosphamide Drug
- Doxorubicin Hydrochloride Drug
- Nivolumab Biological
- Prednisone Drug
- Quality-of-Life Assessment Other
- Rituximab Biological
- Vincristine Sulfate Drug
Drug · Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 19, 2018
- Primary completion
- Dec 10, 2024
- Completion
- Jun 10, 2025
- Last update posted
- Aug 14, 2022
2018 – 2025
United States locations
- U.S. sites
- 4
- U.S. states
- 1
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Northwestern University | Chicago | Illinois | 60611 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Northwestern University- Lake Forest Hospital | Lake Forest | Illinois | 60045 | — |
| Northwestern Medicine: Delnor, DuPage, Warrenville, Kishwaukee (West Region) | Warrenville | Illinois | 60555 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03704714, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 14, 2022 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03704714 live on ClinicalTrials.gov.